Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 5,560,000 shares, a decline of 8.7% from the September 30th total of 6,090,000 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio is currently 3.5 days.

Analysts Set New Price Targets

Several brokerages have commented on ADAP. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th. StockNews.com raised Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after purchasing an additional 1,662,184 shares during the last quarter. Renaissance Technologies LLC grew its position in Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after acquiring an additional 394,566 shares during the last quarter. Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics during the first quarter worth approximately $143,000. Fullcircle Wealth LLC purchased a new position in shares of Adaptimmune Therapeutics during the third quarter worth approximately $33,000. Finally, Vontobel Holding Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Down 4.4 %

Shares of ADAP opened at $0.70 on Wednesday. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05. The company has a market capitalization of $173.89 million, a P/E ratio of -0.95 and a beta of 2.20. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. The firm’s 50 day simple moving average is $1.00 and its 200 day simple moving average is $1.06.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. Adaptimmune Therapeutics had a negative net margin of 51.25% and a negative return on equity of 116.80%. The firm had revenue of $128.23 million for the quarter, compared to analysts’ expectations of $58.00 million. Sell-side analysts forecast that Adaptimmune Therapeutics will post -0.23 earnings per share for the current fiscal year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.